Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Access expired on Tuesday, June 16, 2020

This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.

Already Have An Account? Log in Now

featured

Journal Scan / Research · May 16, 2020

Female Gender Predicts Favorable Prognosis in Patients With Nonmetastatic ccRCC Undergoing Curative Surgery

Clinical Genitourinary Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
Female Gender Predicts Favorable Prognosis in Patients With Non-Metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC)
Clin Genitourin Cancer 2020 Apr 01;18(2)111-116.e1, H Fukushima, K Saito, Y Yasuda, H Tanaka, D Patil, BH Cotta, SH Patel, VA Master, IH Derweesh, Y Fujii

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading